Skip to content
value.today

Omniome, Inc.

Total raised
$100 M
2 rounds on record
Latest round
$60 M
Nov 2019
First round on record
Jun 2018
Today
Acquired
Acquired by Pacific Biosciences of California, Inc.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Omniome, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Omniome, IncPacific Biosciences of California, Inc.2023—$101 M—Annual report

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Omniome, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2019$60 MNo. 2$50 to $250 million

Omniome, Inc.: Raise no. 2, Nov 2019

Investors in this round

2 investors had bought by the notice of Dec 11, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arnold S. Oliphant · Executive Officer
  • Catherine S. Lee · Executive Officer
  • David S. Mullarkey · Executive Officer, Director
  • Kelly S. Perez · Executive Officer
  • Ken S. Song, M.D., Ph.D. · Executive Officer, Director
  • Dan S. Zabrowski · Director
  • David S. Cruikshank · Director
  • Kim S. Kamdar, Ph.D. · Director
  • Michael S. Yi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Catherine Lee, Secretary. Source: SEC Form D, newest notice filed Dec 11, 2019. Read the notice at the SEC.

equitySEC
Jun 2018$40 MNo. 1$10 to $50 million

Omniome, Inc.: Raise no. 1, Jun 2018

Investors in this round

9 investors had bought by the notice of Feb 26, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arnold S. Oliphant · Executive Officer
  • David S. Mullarkey · Executive Officer, Director
  • John S. Murphy, Ph.D. · Executive Officer
  • Kelly S. Perez · Executive Officer
  • Ken S. Song, M.D., Ph.D. · Executive Officer, Director
  • Boris S. Nikolic, M.D. · Director
  • Dan S. Zabrowski · Director
  • David S. Cruikshank · Director
  • Kim S. Kamdar, Ph.D. · Director
  • Michael S. Yi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian J. Cuneo, Secretary. Source: SEC Form D, newest notice filed Feb 26, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Omniome, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2019).

    SEC Form D · Dec 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2019

That is all the official record says: Omniome, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Omniome, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Omniome, Inc.
NameRoleNamed in
Arnold S. OliphantExecutive officerDec 2019
Catherine S. LeeExecutive officerDec 2019
David S. MullarkeyExecutive officerDec 2019
Kelly S. PerezExecutive officerDec 2019
Ken S. Song, M.D., Ph.D.Executive officerDec 2019
John S. Murphy, Ph.D.Executive officerFeb 2019
Dan S. ZabrowskiDirectorDec 2019
David S. CruikshankDirectorDec 2019
David S. MullarkeyDirectorDec 2019
Ken S. Song, M.D., Ph.D.DirectorDec 2019
Kim S. Kamdar, Ph.D.DirectorDec 2019
Michael S. YiDirectorDec 2019
Boris S. Nikolic, M.D.DirectorFeb 2019

Acquired (Jan 1, 2023). Acquired by Pacific Biosciences of California, Inc..